REAL LIFE TREATMENT DURATION OF SORAFENIB OR SUNITINIB IN FIRST LINE METASTATIC RENAL CELL CARCINOMA PATIENTS-A COMPARATIVE ANALYSIS

被引：0
|
作者：
Hammerman, A. [1 ]
Klang, S. H. [1 ]
Liebermann, N. [1 ]
机构：
[1] Clalit Hlth Serv, Tel Aviv, Israel
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74272-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A260 / A260
页数：1
相关论文
共 50 条
  • [1] Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma
    Park, Seong Joon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongcheol
    Ahn, Jin-Hee
    Lee, Dae-Ho
    Ahn, Shin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    CHEMOTHERAPY, 2012, 58 (06) : 468 - 474
  • [2] COMPARATIVE EFFICACY OF SUNITINIB VERSUS SORAFENIB AS THE FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Park, S. J.
    Lee, J.
    Park, I.
    Park, K.
    Ahn, J.
    Lee, D. H.
    Song, C.
    Hong, J. H.
    Kim, C.
    Ahn, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 287 - 288
  • [3] Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patients with metastatic renal cell carcinoma.
    Park, Seongjoon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongchel
    Ahn, Jin-Hee
    Lee, Dae Ho
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma
    Hiles, Jon J.
    Kolesar, Jill M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (02) : 123 - 131
  • [5] Cardiac involvement in patients with sorafenib or sunitinib treatment for metastatic renal cell carcinoma
    Schmidinger, M.
    Vogl, U. M.
    Schukro, C.
    Bojic, A.
    Bojic, M.
    Schmidinger, H.
    Zielinski, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma
    Schlemmer, Marcus
    Spek, Annabel
    Rodler, Severin
    Schott, Melanie
    Casuscelli, Jozefina
    Staehler, Michael
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (03)
  • [7] Sorafenib versus sunitinib as first-line treatment in metastatic renal cell carcinoma: Largest multicenter retrospective analysis.
    Sheng, Xinan
    Zhang, Hailiang
    Li, Xuesong
    Chi, Zhihong
    He, Zhisong
    Ye, Dingwei
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [8] Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency
    Khan, G.
    Golshayan, A.
    Elson, P.
    Wood, L.
    Garcia, J.
    Bukowski, R.
    Rini, B.
    ANNALS OF ONCOLOGY, 2010, 21 (08) : 1618 - 1622
  • [9] Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma
    Santoni, Matteo
    Conti, Alessandro
    Porta, Camillo
    Procopio, Giuseppe
    Sternberg, Cora N.
    Basso, Umberto
    De Giorgi, Ugo
    Bracarda, Sergio
    Rizzo, Mimma
    Ortega, Cinzia
    Massari, Francesco
    Iacovelli, Roberto
    Derosa, Lisa
    Masini, Cristina
    Milella, Michele
    Di Lorenzo, Giuseppe
    Atzori, Francesco
    Pagano, Maria
    Buti, Sebastiano
    De Vivo, Rocco
    Mosca, Alessandra
    Rossi, Marta
    Paglino, Chiara
    Verzoni, Elena
    Cerbone, Linda
    Muzzonigro, Giovanni
    Falconi, Massimo
    Montironi, Rodolfo
    Burattini, Luciano
    Santini, Daniele
    Cascinu, Stefano
    JOURNAL OF UROLOGY, 2015, 193 (01): : 41 - 47
  • [10] Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib
    Grassi, Paolo
    Verzoni, Elena
    Porcu, Luca
    Iacovelli, Roberto
    de Braud, Filippo
    Procopio, Giuseppe
    THERAPEUTIC ADVANCES IN UROLOGY, 2015, 7 (02) : 59 - 68
12345